While approximately 80% of endometrial cancers carry a PI3K/AKT/mTOR pathway mutation [1, 2], surprisingly there are no approved PI3K/AKT/mTOR pathway targeted agents for this disease. This evidence concerns the gene MTOR and endometrial cancer.